Company Description
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers.
The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA.
The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
| Country | Ireland |
| Founded | 1989 |
| IPO Date | Apr 1, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Aaron Berg |
Contact Details
Address: One Central Plaza, 5th Floor Dublin 2, D02 K7K5 Ireland | |
| Phone | 353 0 166 99020 |
| Website | amarincorp.com |
Stock Details
| Ticker Symbol | AMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000897448 |
| CUSIP Number | 023111206 |
| ISIN Number | US0231112063 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aaron D. Berg | Chief Executive Officer, President and Director |
| Dr. Steven B. Ketchum Ph.D. | Executive Vice President, President of Research and Development and Chief Scientific Officer |
| Jonathan N. Provoost | Executive Vice President, Chief Legal and Compliance Officer and Secretary |
| Peter Fishman | Chief Financial Officer |
| Jordan Zwick | Senior Vice President of Corporate Business Development and Investor Relations |
| Laurent Abuaf | President of Europe and Senior Vice President |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs |
| Dr. David Keenan Ph.D. | Executive Vice President of Technical Operations and President of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | ARS | Filing |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | PRER14A | Filing |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 25, 2025 | SCHEDULE 13D/A | Filing |
| Mar 12, 2025 | F-6 POS | Post-effective amendments for immediately effective filing |
| Mar 12, 2025 | 10-K | Annual Report |